Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.

Yu X, Ai J, Cai L, Jing Y, Wang D, Dong J, Pascal LE, Zhang J, Luo R, Wang Z.

Oncotarget. 2016 Apr 5. doi: 10.18632/oncotarget.8588. [Epub ahead of print]

2.
3.

5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.

Pascal LE, Masoodi KZ, O'Malley KJ, Shevrin D, Gingrich JR, Parikh RA, Wang Z.

J Urol. 2015 Apr;193(4):1388-93. doi: 10.1016/j.juro.2014.10.101. Epub 2014 Oct 31.

4.

Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.

Garcia RR, Masoodi KZ, Pascal LE, Nelson JB, Wang Z.

Am J Clin Exp Urol. 2014 Apr 5;2(1):82-91. eCollection 2014.

5.

Unzipping androgen action through ZIP9: a novel membrane androgen receptor.

Pascal LE, Wang Z.

Endocrinology. 2014 Nov;155(11):4120-3. doi: 10.1210/en.2014-1749. No abstract available.

PMID:
25325426
6.

Androgen receptor gene mutation, rearrangement, polymorphism.

Eisermann K, Wang D, Jing Y, Pascal LE, Wang Z.

Transl Androl Urol. 2013 Sep 1;2(3):137-147.

7.

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.

Parikh RA, Pascal LE, Davies BJ, Wang Z.

Asian J Androl. 2014 Jul-Aug;16(4):505-10. doi: 10.4103/1008-682X.125410. Review.

8.

Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.

O'Malley KJ, Eisermann K, Pascal LE, Parwani AV, Majima T, Graham L, Hrebinko K, Acquafondata M, Stewart NA, Nelson JB, Yoshimura N, Wang Z.

Prostate. 2014 Jun;74(8):892-900. doi: 10.1002/pros.22807. Epub 2014 Apr 7.

9.

The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.

Dar JA, Masoodi KZ, Eisermann K, Isharwal S, Ai J, Pascal LE, Nelson JB, Wang Z.

J Steroid Biochem Mol Biol. 2014 Sep;143:473-80. doi: 10.1016/j.jsbmb.2014.03.004. Epub 2014 Mar 22.

10.

Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice.

Pascal LE, Ai J, Masoodi KZ, Wang Y, Wang D, Eisermann K, Rigatti LH, O'Malley KJ, Ma HM, Wang X, Dar JA, Parwani AV, Simons BW, Ittman MM, Li L, Davies BJ, Wang Z.

PLoS One. 2013 Nov 18;8(11):e79542. doi: 10.1371/journal.pone.0079542. eCollection 2013.

11.

Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.

Pascal LE, Wang Z.

Asian J Androl. 2013 Nov;15(6):717-8. doi: 10.1038/aja.2013.115. Epub 2013 Sep 30.

12.

Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.

Ai J, Pascal LE, O'Malley KJ, Dar JA, Isharwal S, Qiao Z, Ren B, Rigatti LH, Dhir R, Xiao W, Nelson JB, Wang Z.

Oncogene. 2014 May 1;33(18):2286-94. doi: 10.1038/onc.2013.190. Epub 2013 May 27.

13.

5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

Masoodi KZ, Ramos Garcia R, Pascal LE, Wang Y, Ma HM, O'Malley K, Eisermann K, Shevrin DH, Nguyen HM, Vessella RL, Nelson JB, Parikh RA, Wang Z.

Endocrinology. 2013 Jul;154(7):2296-307. doi: 10.1210/en.2012-2077. Epub 2013 May 13.

14.

Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.

Su F, Correa BR, Luo J, Vencio RZ, Pascal LE, Wang Z.

Cancer Microenviron. 2013 Dec;6(3):247-61. doi: 10.1007/s12307-013-0132-4. Epub 2013 Feb 26.

15.

Stromal-epithelial interactions in early neoplasia.

Liu AY, Pascal LE, Vêncio RZ, Vêncio EF.

Cancer Biomark. 2010;9(1-6):141-55. doi: 10.3233/CBM-2011-0174.

PMID:
22112474
16.

Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate.

Liu J, Pascal LE, Isharwal S, Metzger D, Ramos Garcia R, Pilch J, Kasper S, Williams K, Basse PH, Nelson JB, Chambon P, Wang Z.

Mol Endocrinol. 2011 Nov;25(11):1849-57. doi: 10.1210/me.2011-1081. Epub 2011 Sep 22.

17.

EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.

Pascal LE, Ai J, Rigatti LH, Lipton AK, Xiao W, Gnarra JR, Wang Z.

Angiogenesis. 2011 Sep;14(3):331-43. doi: 10.1007/s10456-011-9217-1. Epub 2011 Jun 3.

18.

Lineage relationship of prostate cancer cell types based on gene expression.

Pascal LE, Vêncio RZ, Vessella RL, Ware CB, Vêncio EF, Denyer G, Liu AY.

BMC Med Genomics. 2011 May 23;4:46. doi: 10.1186/1755-8794-4-46.

19.

Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells.

Pascal LE, Ai J, Vêncio RZ, Vêncio EF, Zhou Y, Page LS, True LD, Wang Z, Liu AY.

Cancer Microenviron. 2011 Jan 7;4(1):51-9. doi: 10.1007/s12307-010-0061-4.

20.

Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells.

Vêncio EF, Pascal LE, Page LS, Denyer G, Wang AJ, Ruohola-Baker H, Zhang S, Wang K, Galas DJ, Liu AY.

J Cell Physiol. 2011 Jun;226(6):1479-88. doi: 10.1002/jcp.22464.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk